SCHEMBL2136471

SCHEMBL2136471

CC(NC(=O)CCc1ccc(C(F)(F)F)cc1)c1ccc(OCC(F)(F)F)cn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1I Q9P0X4 4/20 0.68
CACNA1G O43497 2/20 0.68
CACNA1H O95180 2/20 0.68
CNR2 P34972 1/20 0.68
KCNH2 Q12809 1/20 0.68
SLC22A12 Q96S37 1/20 0.45
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.43
UTS2R Q9UKP6 3/20 0.42
MCHR1 Q99705 2/20 0.42
GPR139 Q6DWJ6 1/20 0.42
FFAR1 O14842 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
ENPP2 Q13822 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2136467 1.00 CACNA1I (0.68) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL12999290 0.91 CACNA1I (0.66) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1060457 0.90 CACNA1I (0.82) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2136596 0.86 CACNA1I (0.66) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2136610 0.86 CACNA1I (0.66) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2132242 0.84 CACNA1I (0.61) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2132250 0.84 CACNA1I (0.61) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2135633 0.84 CACNA1I (0.62) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2135644 0.84 CACNA1I (0.62) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL4370770 0.83 CACNA1I (0.77) CACNA1ICACNA1GCACNA1HCNR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632899-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RaQualia Pharma Inc. (JP) 2020-04-08 EP disclosed
US-9101616-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2015-08-11 US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H CACNA1I 1/4885CACNA1G 2/4885CACNA1H 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.